Kyntra Bio
KYNB
151 hedge funds and large institutions have $1.23B invested in Kyntra Bio in 2017 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 70 increasing their positions, 38 reducing their positions, and 12 closing their positions.
84% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 38
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
60% more capital invested
Capital invested by funds: $767M → $1.23B (+$459M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
5% more funds holding
Funds holding: 144 → 151 (+7)
0.22% more ownership
Funds ownership: 1.95% → 2.17% (+0.22%)
42% less call options, than puts
Call options by funds: $7.83M | Put options by funds: $13.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$45.7M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$43M |
| 3 |
Janus Henderson Group
London,
|
+$39.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.2M |
| 5 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$20.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$5.37M |
| 2 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$5.15M |
| 3 |
SIM
Spark Investment Management
New York
|
-$4.75M |
| 4 |
Millennium Management
New York
|
-$3.53M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$2.78M |
KYNB Hedge Fund Activity: Q2 2017 in Review
151 of the 4,021 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q2 2017, worth a combined $1.23B — up 60% from $767M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new KYNB positions and 12 closed out — a net gain of 8 holders — while 70 added to existing stakes and 38 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $45.7M. The largest seller was Renaissance Technologies, cutting an estimated $5.37M.
- 151 institutional investors held Kyntra Bio (KYNB) as of Q2 2017, up from 144 in Q1 2017.
- Funds reported $1.23B of Kyntra Bio stock for Q2 2017, up 60% quarter-over-quarter.
- 20 funds opened new Kyntra Bio positions in Q2 2017 and 12 closed out, a net change of +8 holders.
- The largest Kyntra Bio buyer in Q2 2017 was Fidelity Investments, an estimated $45.7M added.
- The largest Kyntra Bio seller in Q2 2017 was Renaissance Technologies, an estimated $5.37M sold.
Based on aggregated 13F filings for Q2 2017.